Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2019
Price : $35 *
At a glance
- Drugs Capmatinib (Primary) ; Erlotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 11 Jun 2019 Planned End Date changed from 1 Dec 2018 to 30 Jun 2020.
- 11 Jun 2019 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2019.
- 11 Jun 2019 Status changed from recruiting to active, no longer recruiting.